Glucagon‐like peptide‐1 receptor agonists (GLP‐1 agonists) have transformed the management of type 2 diabetes and obesity, providing substantial benefits for glycaemic control, weight reduction and cardiometabolic health [1, 2, 3, 4]. Their use is rapidly expanding across both general and specialist practices, with an increasing number of patients also accessing these agents privately for weight management [5, 6]. However, ongoing concern has been raised about a potential association between GLP‐1 agonists and thyroid cancer, in particular medullary thyroid cancer (MTC).
Preclinical rodent studies have found that chronic GLP‐1 agonist exposure stimulates calcitonin secretion, induces C‐cell hyperplasia and increases the incidence of MTC in a dose‐ and drug‐dependent manner [7, 8]. Based on this preclinical data, the US Food and Drug Administration has issued a boxed warning, contraindicating the use of GLP‐1 agonists in those with a personal or family history of MTC or Multiple Endocrine Neoplasia Type 2 (MEN 2) [9]. However, these findings have not been replicated in primates or humans, whose C‐cells exhibit minimal GLP‐1 receptor activity [10, 11, 12, 13, 14].
Clinical evidence remains mixed, but increasingly reassuring. Importantly, no randomised controlled trial in humans has demonstrated a consistent or statistically robust increased incidence of thyroid cancer associated with GLP‐1 receptor agonist therapy [15, 16]. Some pharmacovigilance reports and observational studies have suggested a moderately elevated risk of thyroid cancer [14, 17, 18, 19, 20]. However, large population‐based studies and meta‐analyses found no significant association between GLP‐1 agonist use and thyroid cancer [15, 16, 21, 22, 23, 24, 25, 26, 27, 28]. A recent international meta‐analysis of 98,147 patients found no overall excess risk of thyroid cancer in GLP‐1 agonist users compared with patients treated with Dipeptidyl Peptidase‐4 (DPP‐4) inhibitors (adjusted HR: 0.81, 95% CI 0.59−1.12) [22]. However, long‐term follow‐up is still required. It is also notable that both obesity and diabetes independently increase thyroid cancer risk, complicating the interpretation of observational data [29, 30].
Robust data examining the safety of GLP‐1 agonists in patients who have previously been treated for thyroid cancer is limited. For differentiated thyroid cancer (including papillary, follicular and oncocytic subtypes), GLP‐1 agonists may be used alongside standard oncological surveillance where clinically indicated. A 2022 systematic review found no increased risk of hyperthyroidism, hypothyroidism, thyroiditis, nodules or goitre with GLP‐1 agonists when compared with controls [16]. However, use of GLP‐1 agonists should be avoided in patients with a history of MTC, known pathogenic germline RET variants or a family history of MEN2. For this patient subgroup, initiation of GLP‐1 agonists should only be considered in exceptional cases within a multidisciplinary (MDT) setting. A statement for patients has also been prepared, included as an appendix, to support clear communication and shared decision‐making between clinicians and individuals considering or currently using GLP‐1 agonists (Appendix S1).
Overall, current available evidence suggests no indication of a clinically meaningful short‐term increase in thyroid cancer risk following GLP‐1 agonist initiation. In October 2023, the European Medicines Agency (EMA)'s safety committee Pharmacovigilance Risk Assessment Committee (PRAC) concluded that ‘the available evidence does not support a causal association between [GLP‐1] receptor agonists… and cancer of the thyroid’ [31]. The benefits of therapy are likely to outweigh any potential thyroid‐related risks for most patients. Routine calcitonin measurement or thyroid ultrasound screening is not recommended in unselected patients. Ongoing long‐term surveillance studies will be essential to fully clarify potential late effects.
Funding
The authors received no specific funding for this work.
Conflicts of Interest
The authors declare no conflicts of interest.
Supporting information
Appendix 1: GLP‐1 Medication and Thyroid Cancer ‐ Information for Patients.
Data Availability Statement
Data sharing is not applicable to this article, as no data sets were generated or analysed during the current study.
References
- 1. Wilding J. P. H., Batterham R. L., Calanna S., et al., “Once‐Weekly Semaglutide in Adults With Overweight or Obesity,” New England Journal of Medicine 384, no. 11 (March 2021): 989–1002. [DOI] [PubMed] [Google Scholar]
- 2. McGuire D. K., Marx N., Mulvagh S. L., et al., “Oral Semaglutide and Cardiovascular Outcomes in High‐Risk Type 2 Diabetes,” New England Journal of Medicine 392, no. 20 (May 2025): 2001–2012. [DOI] [PubMed] [Google Scholar]
- 3. Marso S. P., Daniels G. H., Brown‐Frandsen K., et al., “Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes,” New England Journal of Medicine 375, no. 4 (July 2016): 311–322. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Newsome P. N., Buchholtz K., Cusi K., et al., “A Placebo‐Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis,” New England Journal of Medicine 384, no. 12 (March 2021): 1113–1124. [DOI] [PubMed] [Google Scholar]
- 5. Watanabe J. H., Kwon J., Nan B., and Reikes A., “Trends in Glucagon‐Like Peptide 1 Receptor Agonist Use, 2014 to 2022,” Journal of the American Pharmacists Association 64, no. 1 (January 2024): 133–138. [DOI] [PubMed] [Google Scholar]
- 6. Mahase E., “GLP‐1 Agonists: US Sees 700% Increase Over Four Years in Number of Patients Without Diabetes Starting Treatment,” BMJ 386 (July 2024): q1645. [DOI] [PubMed] [Google Scholar]
- 7. Madsen L. W., Knauf J. A., Gotfredsen C., et al., “GLP‐1 Receptor Agonists and the Thyroid: C‐Cell Effects in Mice Are Mediated via the GLP‐1 Receptor and Not Associated With RET Activation,” Endocrinology 153, no. 3 (March 2012): 1538–1547. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Bjerre Knudsen L., Madsen L. W., Andersen S., et al., “Glucagon‐Like Peptide‐1 Receptor Agonists Activate Rodent Thyroid C‐Cells Causing Calcitonin Release and C‐Cell Proliferation,” Endocrinology 151, no. 4 (April 2010): 1473–1486. [DOI] [PubMed] [Google Scholar]
- 9.“Highlights of Prescribing Information: OZEMPIC (Semaglutide) Injection, for Subcutaneous Use,” US Food and Drug Administration, 2023, https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209637s020s021lbl.pdf.
- 10. Bethel M. A., Patel R. A., Thompson V. P., et al., “Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL),” Diabetes Care 42, no. 6 (June 2019): 1075–1080. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Hegedüs L., Sherman S. I., Tuttle R. M., et al., “No Evidence of Increase in Calcitonin Concentrations or Development of C‐Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial,” Diabetes Care 41, no. 3 (March 2018): 620–622. [DOI] [PubMed] [Google Scholar]
- 12. Rosol T. J., “On‐Target Effects of GLP‐1 Receptor Agonists on Thyroid C‐Cells in Rats and Mice,” Toxicologic Pathology 41, no. 2 (February 2013): 303–309. [DOI] [PubMed] [Google Scholar]
- 13. Vahle J. L., Byrd R. A., Blackbourne J. L., et al., “Effects of Dulaglutide on Thyroid C Cells and Serum Calcitonin in Male Monkeys,” Endocrinology 156, no. 7 (July 2015): 2409–2416. [DOI] [PubMed] [Google Scholar]
- 14. Mali G., Ahuja V., and Dubey K., “Glucagon‐Like Peptide‐1 Analogues and Thyroid Cancer: An Analysis of Cases Reported in the European Pharmacovigilance Database,” Journal of Clinical Pharmacy and Therapeutics 46, no. 1 (February 2021): 99–105. [DOI] [PubMed] [Google Scholar]
- 15. Duchemin L., Morice A., Morice P. M., et al., “Risk of Thyroid Cancer Related to Glucagon‐Like Peptide‐1 Receptor Agonists: A Systematic Review With Meta‐Analysis of Harms of Randomized Controlled Trials,” Diabetes, Obesity and Metabolism 27, no. 8 (August 2025): 4607–4610. [DOI] [PubMed] [Google Scholar]
- 16. Hu W., Song R., Cheng R., et al., “Use of GLP‐1 Receptor Agonists and Occurrence of Thyroid Disorders: A Meta‐Analysis of Randomized Controlled Trials,” Frontiers in Endocrinology (Lausanne) 13 (July 2022): 927859. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Wu T., Zhang Y., Shi Y., et al., “Safety of Glucagon‐Like Peptide‐1 Receptor Agonists: A Real‐World Study Based on the US FDA Adverse Event Reporting System Database,” Clinical Drug Investigation 42, no. 11 (November 2022): 965–975. [DOI] [PubMed] [Google Scholar]
- 18. Bezin J., Gouverneur A., Pénichon M., et al., “GLP‐1 Receptor Agonists and the Risk of Thyroid Cancer,” Diabetes Care 46, no. 2 (February 2023): 384–390. [DOI] [PubMed] [Google Scholar]
- 19. Silverii G. A., Monami M., Gallo M., et al., “Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Thyroid Cancer: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials,” Diabetes, Obesity and Metabolism 26, no. 3 (March 2024): 891–900. [DOI] [PubMed] [Google Scholar]
- 20. Brito J. P., Herrin J., Swarna K. S., et al., “GLP‐1RA Use and Thyroid Cancer Risk,” JAMA Otolaryngology–Head & Neck Surgery 151, no. 3 (March 2025): 243. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Pasternak B., Wintzell V., Hviid A., et al., “Glucagon‐Like Peptide 1 Receptor Agonist Use and Risk of Thyroid Cancer: Scandinavian Cohort Study,” BMJ 385 (April 2024): e078225. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Baxter S. M., Lund L. C., Andersen J. H., et al., “Glucagon‐Like Peptide 1 Receptor Agonists and Risk of Thyroid Cancer: An International Multisite Cohort Study,” Thyroid 35, no. 1 (January 2025): 69–78. [DOI] [PubMed] [Google Scholar]
- 23. Alves C., Batel‐Marques F., and Macedo A. F., “A Meta‐Analysis of Serious Adverse Events Reported With Exenatide and Liraglutide: Acute Pancreatitis and Cancer,” Diabetes Research and Clinical Practice 98, no. 2 (November 2012): 271–284. [DOI] [PubMed] [Google Scholar]
- 24. Wang L., Xu R., Kaelber D. C., and Berger N. A., “Glucagon‐Like Peptide 1 Receptor Agonists and 13 Obesity‐Associated Cancers in Patients With Type 2 Diabetes,” JAMA Network Open 7, no. 7 (July 2024): e2421305. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Morales D. R., Bu F., Viernes B., et al., “Risk of Thyroid Tumors With GLP‐1 Receptor Agonists: A Retrospective Cohort Study,” Diabetes Care 48, no. 8 (August 2025): 1386–1394. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Bea S., Son H., Bae J. H., Cho S. W., Shin J. Y., and Cho Y. M., “Risk of Thyroid Cancer Associated With Glucagon‐Like Peptide‐1 Receptor Agonists and Dipeptidyl Peptidase‐4 Inhibitors in Patients With Type 2 Diabetes: A Population‐Based Cohort Study,” Diabetes, Obesity and Metabolism 26, no. 1 (January 2024): 108–117. [DOI] [PubMed] [Google Scholar]
- 27. Lu Y., Dai H., Tang H., et al., “Association of Glucagon‐Like Peptide‐1 Receptor Agonists With Cancer Risk in Older Adults With Type 2 Diabetes,” Obesity (Silver Spring), ahead of print, August 21, 2025: 1–13, 10.1002/oby.24366. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Kim M., Kim S. C., Kim J., and Kim B. H., “Use of Glucagon‐Like Peptide‐1 Receptor Agonists Does Not Increase the Risk of Cancer in Patients With Type 2 Diabetes Mellitus,” Diabetes & Metabolism Journal 49, no. 1 (January 2025): 49–59. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Shin A., Cho S., Jang D., et al., “Body Mass Index and Thyroid Cancer Risk: A Pooled Analysis of Half a Million Men and Women in the Asia Cohort Consortium,” Thyroid 32, no. 3 (March 2022): 306–314. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. Renehan A. G., Tyson M., Egger M., Heller R. F., and Zwahlen M., “Body‐Mass Index and Incidence of Cancer: A Systematic Review and Meta‐Analysis of Prospective Observational Studies,” Lancet 371, no. 9612 (February 2008): 569–578. [DOI] [PubMed] [Google Scholar]
- 31.“Meeting Highlights: Pharmacovigilance Risk Assessment Committee (PRAC), 23–26 October 2023,” European Medicines Agency (EMA), Amsterdam, 2023, https://www.ema.europa.eu/en/news.
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Appendix 1: GLP‐1 Medication and Thyroid Cancer ‐ Information for Patients.
Data Availability Statement
Data sharing is not applicable to this article, as no data sets were generated or analysed during the current study.
